XBIvsXPHETF Comparison
VS
State Street SPDR S&P Biotech ETF (XBI) and State Street SPDR S&P Pharmaceuticals ETF (XPH) belong to the same industry segment: US Health Care. XBI's top 3 sector exposures are Healthcare and Finance. In contrast, XPH's top sector exposures are Healthcare Both XBI and XPH have the same Total Expense Ratio (TER) of 0.35%. XBI is up 24.76% year-to-date (YTD) with +$510M in YTD flows. XPH performs worse with 21.49% YTD performance, and +$172M in YTD flows. Run a side-by-side ETF comparison of XBI and XPH below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
XBI vs XPH performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 07/22/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | XBI XPH | +4.20%+9.52% | +10.82%+17.63% | +24.76%+21.49% | +76.10%+60.82% | +83.33%+66.52% | +19.73%+39.25% |
| Flows | XBI XPH | +$459M+$71M | +$279M+$56M | +$510M+$172M | +$1.45B+$196M | -$425M+$125M | +$1.59B+$127M |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | XBI XPH | +30.98%+24.48% | +26.78%+22.27% | +27.91%+20.33% | +32.90%+20.88% |
| Max drawdown | XBI XPH | -8.13%-8.13% | -9.66%-11.78% | -32.94%-23.45% | -54.07%-31.59% |
| Max drawdown duration | XBI XPH | 13d41d | 76d50d | 331d322d | 1685d1566d |
Trading data
XBI | XPH | |
Last sale 7/24/2026 at 1:30 PM | $150.48 | $67.95 |
| Previous close 07/23/2026 | $152.23 | $68.49 |
| Consolidated volume 07/23/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of June 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
XBI | XPH | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 7/24/2026 at 1:30 PM
Live
Closed
XBI | XPH | |
|---|---|---|
| Last price | $150.48 | $67.95 |
| 1D performance | -1.15% | -0.79% |
| AuM | $10.24 B | $472.62 M |
| E/R | 0.35% | 0.35% |
Characteristics
XBI | XPH | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | State Street Investment Management | State Street Investment Management |
| Benchmark | S&P Biotechnology Select Industry Index | S&P Pharmaceuticals Select Industry Index |
| N° of holdings | 150 | 63 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | January 31, 2006 | June 19, 2006 |
| ESG | No | No |
Advertisement
Exposure
Countries
XBI
USA
95.06%
Other
4.94%
XPH
USA
90.15%
Other
9.85%
Sectors
XBI
Healthcare
99.03%
Other
0.97%
XPH
Healthcare
94.73%
Other
5.27%
Advertisement
Diversification
XBI
Total weight of top 15 holdings out of 15
19.19%
XPH
Total weight of top 15 holdings out of 15
29.74%
Top 15 holdings
Data as of June 30, 2026
XBI
Apogee Therapeutics, Inc.
1.48%
Moderna, Inc.
1.41%
Twist Bioscience Corp.
1.40%
Oruka Therapeutics, Inc.
1.37%
Kymera Therapeutics, Inc.
1.35%
Viking Therapeutics, Inc.
1.30%
Praxis Precision Medicines, Inc.
1.29%
Erasca, Inc.
1.27%
Revolution Medicines, Inc.
1.20%
Rhythm Pharmaceuticals, Inc.
1.20%
CG Oncology, Inc.
1.20%
SELLAS Life Sciences Group, Inc.
1.19%
Vaxcyte, Inc.
1.18%
Dianthus Therapeutics, Inc.
1.18%
Cytokinetics, Inc.
1.17%
XPH
MBX Biosciences, Inc.
2.72%
Alumis, Inc.
2.14%
Trevi Therapeutics, Inc.
2.12%
Enliven Therapeutics, Inc.
2.09%
Amylyx Pharmaceuticals, Inc.
2.04%
Veradermics, Inc.
2.02%
Ligand Pharmaceuticals, Inc.
1.94%
Nuvation Bio, Inc.
1.89%
Edgewise Therapeutics, Inc.
1.88%
Nektar Therapeutics
1.88%
Liquidia Corp.
1.86%
Maze Therapeutics, Inc.
1.85%
Harrow, Inc.
1.81%
EyePoint, Inc.
1.77%
Amneal Pharmaceuticals, Inc.
1.72%
Frequently asked questions about XBI and XPH
How have the XBI and XPH ETFs performed in 2026?
As of July 22, 2026, XBI is up 24.76% year-to-date (YTD), while XPH has returned 21.49%. That puts XBI better performer ahead so far this year.
Which ETF is attracting more investor money: XBI or XPH?
Year-to-date, the XBI ETF saw +$510M in flows, compared to +$172M for XPH.
Which ETF is more volatile: XBI or XPH?
Over the past year, XBI had a volatility of 26.78%, while XPH experienced 22.27%.
Which ETF is bigger: XBI or XPH?
As of July 22, 2026, XBI holds $10.24 B in assets under management (AUM), while XPH manages $472.62 M.
What sectors do the XBI and XPH ETFs invest in?
XBI leans toward sectors like Healthcare. Meanwhile, XPH focuses on Healthcare.
What are the top holdings of the XBI ETF and XPH ETF?
XBI top holdings include Apogee Therapeutics, Inc., Moderna, Inc. and Twist Bioscience Corp.. XPH holds in its top three: MBX Biosciences, Inc., Alumis, Inc. and Trevi Therapeutics, Inc..
Which ETF is more diversified: XBI or XPH?
XBI holds 153 securities with 19.19% of its assets in the top 15. XPH has 63 securities and a top 15 weight of 29.74%.
Advertisement
Latest news about XBI & XPH
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
XBI
Are Biotechnology ETFs In the Midst of a Comeback?
August 20, 2025
XBI
Donald Trump’s Executive Orders: ETF Bulls and Bears
January 24, 2025
XPH
Analyzing the Potential ETF Winners & Losers from The Weight-Loss Drug Craze
November 20, 2023
XPH
Advertisement
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
XBI
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
XBI
Biotech ETFs – Investing in Health Innovation
July 21, 2022
XBI
Advertisement
